Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.20 Average Target Price from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.20.

INO has been the subject of several research analyst reports. StockNews.com upgraded shares of Inovio Pharmaceuticals to a “sell” rating in a research report on Friday, March 21st. Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a report on Wednesday, March 19th. HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Finally, JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.

Inovio Pharmaceuticals Trading Down 1.7 %

NASDAQ INO opened at $1.73 on Wednesday. The company has a 50 day moving average of $2.03 and a 200-day moving average of $3.55. The company has a market cap of $45.15 million, a price-to-earnings ratio of -0.43 and a beta of 0.92. Inovio Pharmaceuticals has a 1-year low of $1.68 and a 1-year high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.18. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. On average, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP increased its stake in shares of Inovio Pharmaceuticals by 72.9% in the fourth quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock valued at $5,708,000 after buying an additional 1,314,796 shares during the period. Stonepine Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $1,922,000. AIGH Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $1,197,000. Bank of America Corp DE increased its position in shares of Inovio Pharmaceuticals by 1,035.2% during the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock worth $1,173,000 after acquiring an additional 584,521 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter worth approximately $549,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.